Repros Therapeutics names Joachim F. Wernicke, Ph.D., M.D. Chief Medical Officer Repros has hired Dr. Wernicke as Chief Medical Officer, effective February 5. Dr. Wernicke joined Eli Lilly in 1984. He retired from Eli Lilly in 2012.
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
Repros Therapeutics has favorable near-term catalysts, says BofA/Merrill BofA/Merrill lowered Repros Therapeutics' price target to $27 from $32 due to competitive pricing and a contraction in the TRT market but says it expects favorable near-term data from Androxal and AndroGel studies. The firm expects the Sept 17 FDA meeting to access DV risks from exogenous testosterone to be favorable. Shares are Buy rated.